Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03334084
Recruitment Status : Completed
First Posted : November 7, 2017
Last Update Posted : July 5, 2019
Sponsor:
Information provided by (Responsible Party):
argenx BVBA

Brief Summary:
The study is a Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects

Condition or disease Intervention/treatment Phase
Bioavailability Study Drug: ARGX-113 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects
Actual Study Start Date : October 11, 2017
Actual Primary Completion Date : September 19, 2018
Actual Study Completion Date : September 19, 2018

Arm Intervention/treatment
Experimental: 1
Scheme 1
Drug: ARGX-113
intravenous or subcutaneous administration

Experimental: 2
Scheme 2
Drug: ARGX-113
intravenous or subcutaneous administration

Experimental: 3
Scheme 3
Drug: ARGX-113
intravenous or subcutaneous administration




Primary Outcome Measures :
  1. bioavailability of a s.c. ARGX-113 formulation [ Time Frame: 1.5 months ]
    AUC0-inf



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male, between 18-55 years of age.
  2. Body mass index (BMI) between 18-30 kg/m2.
  3. Willingness and ability to understand the purpose and risks of the study and provide signed and dated informed consent.
  4. Non-vasectomized male subjects having a female partner of childbearing potential must agree to the use of an effective method of contraception until 90 days after the last administration of study drug.
  5. Subjects have to agree not to donate sperm until 90 days after the last administration of study drug.
  6. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and laboratory findings.
  7. Agree to discontinue and refrain from intake of all medications, except occasional paracetamol use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), at least 2 weeks prior to the first study drug administration. In addition, subjects must agree to the prohibitions and restrictions for this study.
  8. Subject is a non-smoker, and not using any nicotine containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to Screening.

Exclusion Criteria:

  1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  2. Active infection; a recent serious infection (i.e., requiring injectable antimicrobial therapy or hospitalization) within the 8 weeks prior to screening.
  3. Subjects with known clinically relevant immunological disorders.
  4. History of severe allergic or anaphylactic reactions.
  5. Known history or any symptom of clinically significant illness in the 6 months before the first study drug administration.
  6. Presence or having sequelae of gastrointestinal, liver, kidney or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  7. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
  8. Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g., QTcF > 450 ms [millisecond], or a known long QT syndrome). A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality.
  9. Clinically relevant abnormalities detected on vital signs prior to first dosing.
  10. Significant blood loss (including blood donation [> 500 mL]), or had a transfusion of any blood product within 12 weeks prior to the initial study drug administration or plan one within 4 weeks after the end of the study.
  11. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial study drug administration.
  12. The subject has a history of consuming more than 21 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to screening (Note: one unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits).
  13. Consumption of a large quantity of coffee, tea (> 6 cups per day) or equivalent.
  14. Concurrent participation or participation within 90 days prior to the initial study drug administration in a drug/device or biologic investigational research study.
  15. Administration of a vaccine within 60 days prior to initial study drug administration.
  16. Administration of any systemic immunosuppressant agent within 6 months prior to initial study drug administration.
  17. Administration of any systemic steroid within 2 months prior to initial study drug administration.
  18. Administration of an injectable drug within 30 days prior to the initial study drug administration.
  19. Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof who is directly involved in the conduct of the study.
  20. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
  21. Unsuitable vein for infusion and/or blood sampling.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03334084


Locations
Layout table for location information
Netherlands
QPS Netherlands B.V.
Groningen, Netherlands
Sponsors and Collaborators
argenx BVBA
Investigators
Layout table for investigator information
Study Director: Thierry Cousin, MD argenx BVBA
Layout table for additonal information
Responsible Party: argenx BVBA
ClinicalTrials.gov Identifier: NCT03334084    
Other Study ID Numbers: ARGX-1702
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: July 5, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No